【摘 要】
：
Background.Intravenous iron is a recognized therapy of anaemia in chronic haemodialyzed patients,especially in those receiving erythropoietin (Epo),while its role in the anaemia of pre-dialyzed chroni
【机 构】
：
Dr Carol Davila' Teaching Hospital of Nephrology, Bucharest, Romania
【出 处】
：
2013年中国肾性贫血治疗专家共识研讨会
论文部分内容阅读
Background.Intravenous iron is a recognized therapy of anaemia in chronic haemodialyzed patients,especially in those receiving erythropoietin (Epo),while its role in the anaemia of pre-dialyzed chronic renal failure (CRF) patients is much less clear.This study attempted to evaluate the effects of intravenous iron in anaemic pre-dialyzed patients.Methods.Sixty anaemic (haemoglobin < 11 g/dl) nondiabetic patients with moderate CRF [32 males,28 females; mean age 52.2± 12.5 years; mean glomerular filtration rate 36.2±5.2ml/min], without iron deficiency, iron overload or inflammation, without concomitant erythropoietin treatment and without any previous iron therapy were enrolled.Intravenous iron was administered as iron sucrose, 200mg elemental iron per month for 12 months, with 1 month prestudy survey and 1 month follow-up after the last iron dose.Results.Intravenous iron supplementation was associated with a significant increase in haemoglobin (from 9.7 ± 1.1 at the baseline to 11.3 ± 2.5 g/dl after 12 months, a mean increase of 1.6 g/dl), a further 36% of patients reaching the target haemoglobin of 10 g/dl.There was a significant increase in serum iron from 73.9 ± 17.2 to 101.8 ± 12.2 μg/dl, in serum ferritin from 98.0 (24.8-139.0) to 442.5 (86.0-496.0)μg/1 and in transferrin saturation from 21.6±2.6 to 33.6±3.2%.No worsening of renal function, no increase in blood pressure and no other side effects were noted.Conclusions.Intravenous iron therapy in pre-dialysis patients with no Epo seems often to ameliorate the anaemia, avoiding the necessity of Epo or blood transfusions in one-third of pre-dialyzed non-diabetic patients.Intravenous iron supplementation appears to be an effective and safe treatment for anaemia in pre-dialysis CRF patients.
其他文献
铁是合成血红蛋白的基本原料.流行病学及临床的研究证实在慢性肾脏病(CKD)贫血患者中常常存在一定程度的铁缺乏[1,2],铁缺乏也是导致红细胞刺激剂(ESA)治疗反应差的主要原因,予以充足的铁补充 ,不仅可以明显改善贫血,还可以减少ESA的使用剂量,甚至在未使用ESA的情况下也能改善贫血[3,4].因此对于CKD贫血患者需常规进行铁状态的评价,搜寻导致铁缺乏的原因.并根据患者的铁状态予以相应的铁剂补
Introduction Over the last few years, much has been done to develop guidelines on the basis of the strongest possible evidence because this allows an accurate description of the quality and/or degree
Introduction Despite major recent therapeutic improvements, septic shock remains a leading cause of mortality in intensive care patients [1].For more than a decade, it has been advocated [2,3] that th
Sodium ferric gluconate complex in hemodialysis patients:Adverse reactions compared to placebo and iron dextran.Background.Parenteral iron is often required by hemodialysis patients to maintain adequa
The Dialysis Patients Response to Ⅳ Iron with Elevated Ferritin (DRIVE) study demonstrated the efficacy of intravenous ferric gluconate to improve hemoglobin levels in anemic hemodialysis patients who
Background.Parenteral iron therapy is an accepted adjunctive management of anaemia in kidney disease.Newer agents may have fewer severe hypersensitivity adverse events (AE) compared with iron dextrans
Bacterial sepsis is the second leading cause of death among hemodialysis (HD) patients.Iron overload and intravenous iron therapy are linked to bacterial infection.This study examined iron stores, int
High-dose parenteral iron sucrose depresses neutrophil intracellular killing capacity.Background.Iron is essential for the formation of hemoglobin.During long-term treatment with human recombinant ery
The medical care of renal anaemia has received much attention over the past decade, as nephrologists have recognized the increased therapeutic value of erythropoiesis-stimulating agents.The European B
Background and objectives: Optimal hemoglobin targets for chronic kidney disease patients receiving erythropoiesisstimulating agents remain controversial.The effects of different hemoglobin targets on